PRNewsWire
11 Nov 2025, 01:30 UTC · 51w ago
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
Impact · against what's priced in
uniQure faces severe valuation pressure as the FDA deems its Huntington's disease therapy data insufficient for BLA submission, creating an indefinite delay in commercialization. Sportradar's legal situation is a procedural reminder of an existing class action lawsuit.
- QURE−0.90
No priced-in read yet





